POLITICO Studio speaks with Ricardo Marek, President Europe and Canada at Takeda Pharmaceuticals, on why rare diseases need to be a public health priority, and how Europe can remain a leader in life sciences.
BEIJING: Bullish on China’s innovation-driven biopharmaceutical environment, Takeda Pharmaceutical Co vows to further enlarge its investment in China, a top official of the Japanese drugmaker said.
Takeda Pharmaceutical Company has announced the official groundbreaking of its first building to follow the Singapore Green Mark Zero Energy certification scheme
Redirecting to Takeda s Growth and Emerging Markets Business Unit Aims to Deliver Double-Digit Revenue Growth Over Next Decade1 q8dailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from q8dailynews.com Daily Mail and Mail on Sunday newspapers.
Takeda Pharmaceutical Company Limited
Takeda’s Growth and Emerging Markets Business Unit Aims to Deliver Double-Digit Revenue Growth Over Next Decade1
Friday, March 12, 2021 11:40AM IST (6:10AM GMT)
Aiming for Revenues of JPY 1 Trillion (approximately US$9 Billion2) by FY2030
Double-Digit Revenue Growth Expected to be Driven by a Balanced and Focused Geographic Presence, Portfolio of 14 Global Brands and Wave 1 Pipeline Assets
Commitment to Patient Access to Medicines and Addressing Unmet Patient Needs in Emerging Markets Underpin Sustainable Growth
(TSE:4502/NYSE:TAK) (“Takeda”) today outlined its ambition for above-market, double-digit revenue growth of its Growth and Emerging Markets Business Unit (“GEM BU”). The revenue goal of JPY 1 trillion (approximately US$9 billion) by FY2030 represents more than doubling of current revenues in GEM BU. This potential growth will be primarily driven by a balanced geographical focus and targeted portfolio investments